Clinical Observation of Synchronous Chemotherapy with Sintilimab Combined with Respiratory Rehabilitation Training in the Treatment of Advanced Non-Small Cell Lung Cancer
Objective To investigate the clinical efficacy of synchronous chemotherapy with sintilimab combined with respiratory rehabilitation training in the treatment of advanced non-small cell lung cancer(NSCLC),and its effect on patients'lung function and quality of life.Methods A total of 110 patients with advanced NSCLC admitted to the hospital from January 2021 to December 2023 were selected and randomly divided into the observation group and the control group by the random number table method,with 55 cases in each group.The patients in the two groups received routine treatment,while the patients in the control group received synchronous chemotherapy with sintilimab,and the patients in the observation group received respiratory exercise rehabilitation training on the basis of the control group,with chemotherapy lasting for four cycles and respiratory exercise rehabilitation training lasting for three months.Results The objective remission rate and disease control rate in the observation group were 56.36％and 92.73％,which were significantly higher than 36.36％and 78.18％in the control group(P＜0.05).After treatment,the lung function indicators[forced vital capacity(FVC),forced expiratory volume in the first second(FEV1),FEV1/FVC],hypoxia-related indicators[arterial oxygen saturation(SaO2),arterial partial pressure of oxygen(PaO2)],immune function indicators(CD3+,CD4+,CD4+/CD8+),and functional assessment of cancer therapy-lung(FACT-L)score in the two groups were significantly higher than those before treatment(P＜0.05),and those in the observation group were significantly higher than those in the control group(P＜0.05);the lung function indicators[hypoxia-inducible factor-1α(HIF-1α)]and immune function indicator(CD8+)in the two groups were significantly lower than those before treatment(P＜0.05),and those in the observation group were significantly lower than those in the control group(P＜0.05).The incidence of adverse reactions between the observation group and the control group was comparable(14.55％vs.10.91％,P＞0.05).Conclusion Synchronous chemotherapy with sintilimab combined with respiratory rehabilitation training in the treatment of advanced NSCLC has good clinical efficacy and safety,which can improve patients'lung function,hypoxia degree,immune function,and quality of life.
sintilimabrespiratory rehabilitation trainingnon-small cell lung cancerlung functionquality of lifeclinical efficacy
万方数据
维普
